While next-generation sequencing (NGS) has driven recent advances in precision oncology research, it often falls short when identifying the molecular mechanisms underlying many malignancies. As a result, alternative NGS-based approaches are needed to identify oncogenic drivers and potential drug targets.
To address this challenge, Stephen Mack of Baylor College of Medicine has developed a novel approach to assess transcriptional and epigenetic regulatory activity in chemotherapy-resistant brain tumors. In this webinar, he will define a framework for integrating multi-omics NGS data to discover and confirm novel drug targets in high-risk neurological cancer models.
Using tumor glioblastoma, ependymoma, and diffuse intrinsic pontine glioma models, Dr. Mack will demonstrate how integrative analysis of H3K27ac ChIP-seq and RNA-seq data enabled his team to identify molecular pathways that can be inhibited by small-molecule drugs.
For Research Use Only. Not for use in diagnostics procedures.
